Pentosan Polysulfate Sodium Treatment Strongly Linked With Maculopathy and Vision Loss

Patients taking pentosan polysulfate sodium (PPS), which has been on the market for many years, appear to be at greater risk for a newly described maculopathy and vision loss, researchers report, according to Reuters.

“Exposure to PPS, the only FDA-approved oral medication for interstitial cystitis (IC), is strongly linked to a newly described, vision-threatening retinal condition. . . . It’s alarming that a drug that has been on the market for decades is now being implicated in a possible ocular toxicity,” cautioned senior author Dr. Nieraj Jain of Emory University School of Medicine in Atlanta, Georgia.

Read the full article.